At a glance
ClinicalIndex Comparison Record- ✓Adult patients age 18 or older
- ✓Primary or locally recurrent extremity or truncal soft tissue sarcoma
- ✓ECOG performance status 0-2
- ✕History of prior local radiation therapy
- ✕Inability to tolerate treatment position during simulation or treatment
- ✕Tumor originating in retroperitoneal location
- ✕Planned systemic therapy including chemotherapy, targeted agents, and immunotherapy
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PROspective Phase II Trial of Pre-operative Hypofractionated protoN Therapy for Extremity and Truncal Soft Tissue sarcOma
In Brief
A clinical study evaluating hypofractionation for Soft Tissue Sarcoma. Currently recruiting, targeting 40 participants across 1 site.
Detailed Summary
This study is being done to examine whether proton therapy for certain kinds of sarcomas (extremity and trunk soft tissue) is safe and effective. As part of the study, patients will have five fractions of proton therapy before the participants have surgery for the sarcoma. The study will measure wound complications and functional outcomes / quality of life after the procedures. Patients will be asked to complete questionnaires about the treatment and quality of life from the time of enrollment until about two years after surgery. Otherwise, the participants will have standard of care follow ups with the treatment team.
Study Details
Timeline
Interventions
This study is being done to see if hypofractionation in treating sarcoma, will also provide patients with a faster and safer treatment outcome.